Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 384Carcinoma, Non-Small-Cell Lung 242Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 191Neoplasms 178Colorectal Neoplasms 160Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 126Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 113Squamous Cell Carcinoma of Head and Neck 106Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 87Carcinoma, Hepatocellular 79Triple Negative Breast Neoplasms 75Esophageal Neoplasms 75Endometrial Neoplasms 74Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 54Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

repaglinide 1Warfarin 1Omeprazole 1Midazolam 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prostate Cancer Patients × Genitourinary × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡